Safety and efficacy of hypofractionated radiotherapy combined with tyrosine kinase inhibitors in patients with lung metastases after liver transplantation for hepatocellular carcinoma.

Background: Lung metastases often occur after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy of combining hypofractionated radiotherapy (HFRT) with tyrosine kinase inhibitors (TKIs) in patients with lung metastases from HCC following OLT.

Methods: We retrospectively analyzed forty-eight patients with lung metastases post-OLT for HCC, who underwent concurrent HFRT and TKIs between July 2011 and August 2022.